DSM-Firmenich AG 2011 IR
The report highlights Royal DSM's strong performance in 2011, marking the first full year of implementing its 'DSM in motion: driving focused growth' strategy. The company achieved net sales of ’9,048 million and an EBITDA of ’1,296 million, driven by robust growth in high growth economies, which now account for 39% of total sales. Key strategic milestones included the acquisition of Martek and the formation of the anti-infectives joint venture with Sinochem. On the sustainability front, DSM was ranked number one in the Dow Jones Sustainability Index for its sector and improved its energy efficiency by 13% compared to 2008.
Company: DSM-Firmenich AG
Sector: Manufacturing
Country: Switzerland
Year: 2011
Type: IR
Pages: 232
Back to company
DSM-Firmenich AG
Integrated Annual Report
The report highlights Royal DSM's strong performance in 2011, marking the first full year of implementing its 'DSM in motion: driving focused growth' strategy. The company achieved net sales of ’9,048 million and an EBITDA of ’1,296 million, driven by robust growth in high growth economies, which now account for 39% of total sales. Key strategic milestones included the acquisition of Martek and the formation of the anti-infectives joint venture with Sinochem. On the sustainability front, DSM was ranked number one in the Dow Jones Sustainability Index for its sector and improved its energy efficiency by 13% compared to 2008.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Jan 1, 2011 - Dec 31, 2011
Fiscal Year
2011
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women in Management
Workplace Fatalities
Employees